Denali Therapeutics (DNLI) announced the primary analysis of the Phase 1/2 study in 47 participants with Hunter syndrome in the 24-week ...

Citius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (Nasdaq: CTXR) and its oncology-focused subsidiary, Citius ...

Dr. Tycel Phillips discusses the FDA approval of a Calquence combo in MCL, making it the first and only BTK inhibitor ...

Suvarna Arogya Suraksha Trust (SAST), the nodal agency implementing the health schemes of Karnataka, has been directed to ...

The Food and Drug Administration (FDA) has approved Grafapex ™ (treosulfan) for injection with fludarabine as a preparative regimen for allogeneic hematopoietic stem cell transplantation (alloHSCT) in ...

The FDA approved treosulfan (Grafapex) with fludarabine as a preparative regimen for allogeneic hematopoietic stem cell transplantation in patients ages 1 year and older with acute myeloid leukemia ...

Dose interruptions due to an adverse reaction occurred in 44% of patients. The adverse reactions leading to dose interruption in >2 patients were viral infection, infection (pathogen unspecified), ...

DURHAM, N.C., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a biotechnology platform company developing universally implantable, bioengineered ...

1 Division of Infectious Diseases, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA 2 Division of Geriatric Medicine and Gerontology, Department of ...

Pathology and Pyrexia have announced that they’ll hit the road together for a tour of the U.S. starting in March. Dates are below. Seek out tickets here.